Status:

RECRUITING

Abnormal Lipids - Causes and Effects

Lead Sponsor:

Manchester University NHS Foundation Trust

Conditions:

Hypertriglyceridaemia

Eligibility:

All Genders

18+ years

Brief Summary

1. At target LDL-C levels, apoB100 concentrations will be higher than recommended levels in the following populations: 1. Tertiary centre lipid clinic patients with raised TG treated with statins....

Detailed Description

Fats are present in the body in the form of lipid particles containing cholesterol and triglycerides. Lipid particles can deposit in blood vessels, forming atheromas, blocking blood vessels and leadin...

Eligibility Criteria

Inclusion

  • Therapeutic target arm
  • Statin treated patients with and without hypertriglyceridemia.
  • Statin treated patients with type 2 diabetes.
  • Statin treated patients with CKD stages 4 and 5.
  • Nerve function arm
  • •Patients known to have severe hypertriglyceridaemia (defined as triglyceride \>5.5 mmol/l) but not known to have diabetes and matched controls.
  • Genetic screening arm
  • Patients with a documented triglyceride level of more than 10 mmol/l at any time.
  • Criteria for screening for FH and LAL deficiency include non-obese patients (BMI \<30) with low HDL-C (\<1.0 mmol/l male and \<1.3 mmol female), high triglycerides \>1.7 mmol/l, high total cholesterol \>6.2 or LDL cholesterol \>4.7 mmol/l; patients with raised liver alanine aminotransferase (ALT) (1.5 x above ULN) but no metabolic or viral disease or alcohol excess and patients diagnosed with NAFLD with or without hyperlipidaemia.

Exclusion

  • Pregnant and/or breast-feeding women.
  • Significant liver impairment.
  • Patients known to have active malignant disease.
  • Patients treated with medications that could affect lipoprotein metabolism significantly (like atypical antipsychotics, chemotherapy).
  • Untreated hypothyroid and hyperthyroidism (if treated and TFT normal could be recruited).

Key Trial Info

Start Date :

January 23 2014

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 1 2030

Estimated Enrollment :

1396 Patients enrolled

Trial Details

Trial ID

NCT02195050

Start Date

January 23 2014

End Date

December 1 2030

Last Update

May 31 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cardiovascular Trials Unit

Manchester, United Kingdom, M13 9WL